NCT02816021 - Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Melanoma and Other Malignant Neoplasms of SkinMetastatic Melanoma

Interventions

DRUG

Azacitidine

300 mg by mouth daily for 15 days (Days 1-15) of every cycle.

DRUG

Pembrolizumab

200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston